NCT00095563 · OUTCOME

Rate of Stable Disease

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 6 months

What was measured

Number of patients who had Stable disease for more than or equal to 6 months together in both Adenoid cystic carcinoma (ACC) and non-adenoid cyctic carcinoma (non-ACC)

Analysis population: 36 assessable participants, 19 with ACC and 17 with non-ACC.

Groups in this outcome

Treatment (Lapatinib Ditosylate)

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	36

Reported measurements

ACC

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	19

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	9	Not reported	Not reported	Not reported	Not reported

Non-ACC

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	17

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	4	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
9
denoms
counts
group Id
OG000
value
19
units
Participants
title
ACC
categories
measurements
group Id
OG000
value
4
denoms
counts
group Id
OG000
value
17
units
Participants
title
Non-ACC

denoms

counts
group Id
OG000
value
36
units
Participants

description

Number of patients who had Stable disease for more than or equal to 6 months together in both Adenoid cystic carcinoma (ACC) and non-adenoid cyctic carcinoma (non-ACC)

groups

description
Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies
id
OG000
title
Treatment (Lapatinib Ditosylate)

param Type

NUMBER

population Description

36 assessable participants, 19 with ACC and 17 with non-ACC.

reporting Status

POSTED

time Frame

6 months

title

Rate of Stable Disease

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice